Galapagos NV (NASDAQ:GLPG) Given Average Rating of "Hold" by Analysts
Galapagos NV (NASDAQ:GLPG) Given Average Rating of "Hold" by Analysts
Shares of Galapagos NV (NASDAQ:GLPG – Get Rating) have received an average recommendation of "Hold" from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $62.75.
据MarketBeat Ratings报道,加拉帕戈斯公司(纳斯达克代码:GET Rating)的股票得到了目前覆盖该公司的八家券商的平均持有建议。一名投资分析师对该股的评级为卖出建议,四名分析师给出了持有建议,两名分析师给出了买入建议。在过去一年发布该股报告的分析师中,12个月的平均目标价为62.75美元。
Several equities research analysts have commented on the stock. Morgan Stanley cut shares of Galapagos from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $80.00 to $61.00 in a research report on Friday. Jefferies Financial Group cut shares of Galapagos from a "hold" rating to an "underperform" rating in a research report on Monday, July 25th. Finally, Royal Bank of Canada cut their price target on shares of Galapagos from $62.00 to $55.00 in a research report on Monday, August 8th.
几位股票研究分析师对该股发表了评论。在周五的一份研究报告中,摩根士丹利将加拉帕戈斯股票的评级从增持下调至持平,并将该股的目标价从80美元下调至61美元。7月25日,杰富瑞金融集团在一份研究报告中将加拉帕戈斯的股票评级从持有下调至表现不佳。最后,加拿大皇家银行在8月8日星期一的一份研究报告中将加拉帕戈斯股票的目标价从62.00美元下调至55.00美元。
Galapagos Price Performance
加拉帕戈斯的性价比
Shares of GLPG stock opened at $48.16 on Monday. Galapagos has a 12-month low of $46.41 and a 12-month high of $72.11. The firm has a fifty day moving average of $52.80 and a 200-day moving average of $57.55.
周一,GLPG股票开盘报48.16美元。加拉帕戈斯的油价为46.41美元,为12个月低点,12个月高位为72.11美元。该公司的50日移动均线切入位在52.80美元,200日移动均线切入位在57.55美元。
Institutional Investors Weigh In On Galapagos
机构投资者参与加拉帕戈斯
A number of institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Galapagos by 64.7% in the 2nd quarter. FMR LLC now owns 3,568,650 shares of the biotechnology company's stock valued at $199,131,000 after purchasing an additional 1,401,691 shares during the period. 683 Capital Management LLC grew its position in shares of Galapagos by 29.0% during the 4th quarter. 683 Capital Management LLC now owns 905,121 shares of the biotechnology company's stock worth $49,900,000 after purchasing an additional 203,700 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Galapagos by 547.9% during the 4th quarter. Point72 Asset Management L.P. now owns 763,900 shares of the biotechnology company's stock worth $42,114,000 after acquiring an additional 646,000 shares in the last quarter. BlackRock Inc. boosted its position in shares of Galapagos by 46.8% during the 1st quarter. BlackRock Inc. now owns 517,611 shares of the biotechnology company's stock worth $32,103,000 after acquiring an additional 164,912 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its position in shares of Galapagos by 6.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 510,649 shares of the biotechnology company's stock worth $28,494,000 after acquiring an additional 33,034 shares in the last quarter. 19.48% of the stock is owned by institutional investors.
一些机构投资者和对冲基金最近调整了对该公司的持股。FMR LLC在第二季度将其在加拉帕戈斯股票的持有量增加了64.7%。FMR LLC现在拥有这家生物技术公司3,568,650股票,价值199,131,000美元,在此期间又购买了1,401,691股票。683 Capital Management LLC在第四季度将其在加拉帕戈斯股票的头寸增加了29.0%。683 Capital Management LLC现在拥有905,121股这家生物技术公司的股票,价值49,900,000美元,上个季度又购买了203,700股。Point72 Asset Management L.P.在第四季度将其在加拉帕戈斯股票的头寸提高了547.9%。Point72 Asset Management L.P.在上个季度增持了64.6万股后,现在拥有76.39万股这家生物技术公司的股票,价值42,114,000美元。贝莱德股份有限公司在第一季度将其在加拉帕戈斯股票的持仓增加了46.8%。贝莱德股份有限公司在上个季度增持了164,912股后,目前持有这家生物技术公司517,611股股票,价值32,103,000美元。最后,Driehaus Capital Management LLC在第二季度将其在加拉帕戈斯股票的头寸提高了6.9%。Driehaus Capital Management LLC在上个季度增持了33,034股后,现在拥有这家生物技术公司510,649股,价值28,494,000美元。19.48%的股份由机构投资者持有。
About Galapagos
关于加拉帕戈斯
(Get Rating)
(获取评级)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
加拉帕戈斯公司是一家综合性生物制药公司,从事各种药物的发现、开发和商业化,以满足高度未得到满足的医疗需求。其流水线产品包括非戈替尼,一种JAK1抑制剂,正处于临床试验的不同阶段,用于治疗类风湿性关节炎、克罗恩病、溃疡性结肠炎、小肠CD、瘘管性CD、强直性脊柱炎、牛皮癣关节炎和葡萄膜炎。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- 免费获取StockNews.com关于加拉帕戈斯的研究报告(GLPG)
- 电子艺界能扭转电子游戏市场的低迷吗?
- 美元将军是美国小池塘里的大鱼。
- 以下是CPI报告将决定市场底部的原因
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
接受加拉帕戈斯日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对加拉帕戈斯和相关公司的最新新闻和分析师评级的每日简要摘要。